PLCe{open} and the RASSF family in tumour suppression and other functions

Advances in Biological Regulation

Volumn 53, Issue 3, 2013, Pages 258-279

  Chan, Jia Jia ^a   Katan, Matilda ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; PHOSPHOLIPASE C EPSILON; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; APOPTOSIS; CHEMISTRY; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MULTIGENE FAMILY; NEOPLASM; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; APOPTOSIS; HUMANS; MULTIGENE FAMILY; NEOPLASMS; PHOSPHOINOSITIDE PHOSPHOLIPASE C; TUMOR SUPPRESSOR PROTEINS;

EID: 84885831339     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2013.07.008     Document Type: Review

References (121)

1. Akino K., Toyota M., Suzuki H., Mita H., Sasaki Y., Ohe-Toyota M., et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 2005, 129:156-169.
2. Allen N.P., Donninger H., Vos M.D., Eckfeld K., Hesson L., Gordon L., et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007, 26:6203-6211.
3. Aoyama Y., Avruch J., Zhang X.F. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 2004, 23:3426-3433.
4. Avruch J., Praskova M., Ortiz-Vega S., Liu M., Zhang X.F. Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol 2006, 407:290-310.
5. Baksh S., Tommasi S., Fenton S., Yu V.C., Martins L.M., Pfeifer G.P., et al. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell 2005, 18:637-650.
6. Bee C., Moshnikova A., Mellor C.D., Molloy J.E., Koryakina Y., Stieglitz B., et al. Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation. J Biol Chem 2010, 285:16258-16266.
7. Bunney T.D., Harris R., Gandarillas N.L., Josephs M.B., Roe S.M., Sorli S.C., et al. Structural and mechanistic insights into Ras association domains of phospholipase C epsilon. Mol Cell 2006, 21:495-507.
8. Bunney T.D., Katan M. Phospholipase C epsilon: linking second messengers and small GTPases. Trends Cell Biol 2006, 16:640-648.
9. Bunney T.D., Katan M. PLC regulation: emerging pictures for molecular mechanisms. Trends Biochem Sci 2011, 36:88-96.
10. Calvisi D.F., Donninger H., Vos M.D., Birrer M.J., Gordon L., Leaner V., et al. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 2009, 69:4629-4637.
11. Calvisi D.F., Evert M., Dombrowski F. Pathogenetic and prognostic significance of inactivation of RASSF proteins in human hepatocellular carcinoma. Mol Biol Int 2012, 2012:849874.
12. Chan J.J., Flatters D., Rodrigues-Lima F., Yan J., Thalassinos K., Katan M. Comparative analysis of interactions of RASSF1-10. Adv Biol Regul 2013, 53:190-201.
13. Chen L., Johnson R.C., Milgram S.L. P-CIP1, a novel protein that interacts with the cytosolic domain of peptidylglycine alpha-amidating monooxygenase, is associated with endosomes. J Biol Chem 1998, 273:33524-33532.
14. Chow L.S., Lo K.W., Kwong J., Wong A.Y., Huang D.P. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 2004, 12:781-787.
15. Clark J., Freeman J., Donninger H. Loss of RASSF2 enhances tumorigencity of lung cancer cells and confers resistance to chemotherapy. Mol Biol Int 2012, 2012:705948.
16. Cooper W.N., Dickinson R.E., Dallol A., Grigorieva E.V., Pavlova T.V., Hesson L.B., et al. Epigenetic regulation of the Ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 2008, 27:1805-1811.
17. Cooper W.N., Hesson L.B., Matallanas D., Dallol A., von Kriegsheim A., Ward R., et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 2009, 28:2988-2998.
18. Dallol A., Agathanggelou A., Tommasi S., Pfeifer G.P., Maher E.R., Latif F. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res 2005, 65:7653-7659.
19. Dallol A., Hesson L.B., Matallanas D., Cooper W.N., O'Neill E., Maher E.R., et al. RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol 2009, 19:1227-1232.
20. Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-319.
21. Danielsen S.A., Cekaite L., Agesen T.H., Sveen A., Nesbakken A., Thiis-Evensen E., et al. Phospholipase C isozymes are deregulated in colorectal cancer-insights gained from gene set enrichment analysis of the transcriptome. PLoS One 2011, 6:e24419.
22. Dansranjavin T., Wagenlehner F., Gattenloehner S., Steger K., Weidner W., Dammann R., et al. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma. Prostate 2012, 72:1550-1558.
23. Del Re D.P., Matsuda T., Zhai P., Gao S., Clark G.J., Van Der Weyden L., et al. Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J Clin Invest 2010, 120:3555-3567.
24. Dittfeld C., Richter A.M., Steinmann K., Klagge-Ulonska A., Dammann R.H. The SARAH domain of RASSF1A and its tumor suppressor function. Mol Biol Int 2012, 2012:196715.
25. Djos A., Martinsson T., Kogner P., Carén H. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer 2012, 13:40.
26. Donninger H., Hesson L., Vos M., Beebe K., Gordon L., Sidransky D., et al. The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 2010, 30:2608-2620.
27. Donninger H., Barnoud T., Nelson N., Kassler S., Clark J., Cummins T.D., et al. RASSF1A and the rs2073498 cancer associated SNP. Front Oncol 2011, 1:54.
28. Eckfeld K., Hesson L., Vos M.D., Bieche I., Latif F., Clark G.J. RASSF4/AD037 is a potential Ras effector/tumor suppressor of the RASSF family. Cancer Res 2004, 64:8688-8693.
29. El-Kalla M., Onyskiw C., Baksh S. Functional importance of RASSF1A microtubule localization and polymorphisms. Oncogene 2010, 29:5729-5740.
30. Falvella F.S., Manenti G., Spinola M., Pignatiello C., Conti B., Pastorino U., et al. Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene 2006, 25:3934-3938.
31. Fausti F., Di Agostino S., Sacconi A., Strano S., Blandino G. Hippo and RASSF1A pathways: a growing Affair. Mol Biol Int 2012, 2012:307628.
32. Foley C.J., Freedman H., Choo S.L., Onyskiw C., Fu N.Y., Yu V.C., et al. Dynamics of RASSF1A/MOAP-1 association with death receptors. Mol Cell Biol 2008, 28:4520-4535.
33. Fujita H., Fukuhara S., Sakurai A., Yamagishi A., Kamioka Y., Nakaoka Y., et al. Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes. J Biol Chem 2005, 280:5022-5031.
34. Gao B., Xie X.J., Huang C., Shames D.S., Chen T.T., Lewis C.M., et al. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res 2008, 68:22-25.
35. Gazin C., Wajapeyee N., Gobeil S., Virbasius C.M., Green M.R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007, 449:1073-1077.
36. Guerrero-Setas D., Perez-Janices N., Blanco-Fernandez L., Ojer A., Cambra K., Berdasco M., et al. RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer. Mod Pathol 2013, 26:1111-1122.
37. Guo C., Tommasi S., Liu L., Yee J.K., Dammann R., Pfeifer G.P. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol 2007, 17:700-705.
38. Guo C., Zhang X., Pfeifer G.P. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem 2011, 286:6253-6261.
39. Hanahan D., Weinberg R. The hallmarks of cancer. Cell 2000, 100:57-70.
40. Hesson L.B., Dunwell T.L., Cooper W.N., Catchpoole D., Brini A.T., Chiaramonte R., et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009, 8:42.
41. Hill V.K., Underhill-Day N., Krex D., Robel K., Sangan C.B., Summersgill H.R., et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2011, 30:978-989.
42. Hitomi J., Christofferson D.E., Ng A., Yao J., Degterev A., Xavier R.J., et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008, 135:1311-1323.
43. Hwang E., Ryu K.S., Paakkonen K., Guntert P., Cheong H.K., Lim D.S., et al. Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway. Proc Natl Acad Sci U S A 2007, 104:9236-9241.
44. Ikeda M., Hirabayashi S., Fujiwara N., Mori H., Kawata A., Iida J., et al. Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res 2007, 313:1484-1495.
45. Ikeda M., Kawata A., Nishikawa M., Tateishi Y., Yamaguchi M., Nakagawa K., et al. Hippo pathway-dependent and -independent roles of RASSF6. Sci Signal 2009, 2. ra59.
46. Jacquemart I.C., Springs A.E.B., Chen W.E.N.Y. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Int J Oncol 2009, 34:517-528.
47. Katagiri K., Maeda A., Shimonaka M., Kinashi T. RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat Immunol 2003, 4:741-748.
48. Katagiri K., Ohnishi N., Kabashima K., Iyoda T., Takeda N., Shinkai Y., et al. Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking. Nat Immunol 2004, 5:1045-1051.
49. Katagiri K., Imamura M., Kinashi T. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol 2006, 7:919-928.
50. Katagiri K., Ueda Y., Tomiyama T., Yasuda K., Toda Y., Ikehara S., et al. Deficiency of Rap1-binding protein RAPL causes lymphoproliferative disorders through mislocalization of p27kip1. Immunity 2011, 34:24-38.
51. Khokhlatchev A., Rabizadeh S., Xavier R., Nedwidek M., Chen T., Zhang X.-f, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002, 12:253-265.
52. Kitagawa D., Kajiho H., Negishi T., Ura S., Watanabe T., Wada T., et al. Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation. EMBO J 2006, 25:3286-3297.
53. Kudo T., Ikeda M., Nishikawa M., Yang Z., Ohno K., Nakagawa K., et al. The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53. Cancer Res 2012, 72:2901-2911.
54. Kumari G., Mahalingam S. Extracellular signal-regulated kinase 2 (ERK-2) mediated phosphorylation regulates nucleo-cytoplasmic shuttling and cell growth control of Ras-associated tumor suppressor protein, RASSF2. Exp Cell Res 2009, 315:2775-2790.
55. Kumari G., Singhal P.K., Suryaraja R., Mahalingam S. Functional interaction of the Ras effector RASSF5 with the tyrosine kinase Lck: critical role in nucleocytoplasmic transport and cell cycle regulation. J Mol Biol 2010, 397:89-109.
56. Langton P.F., Colombani J., Chan E.H., Wepf A., Gstaiger M., Tapon N. The dASPP-dRASSF8 complex regulates cell-cell adhesion during Drosophila retinal morphogenesis. Curr Biol 2009, 19:1969-1978.
57. Lee C.K., Lee J.H., Lee M.G., Jeong S.I., Ha T.K., Kang M.J., et al. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer 2010, 10:577.
58. Lee C.M., Yang P., Chen L.C., Chen C.C., Wu S.C., Cheng H.Y., et al. A novel role of RASSF9 in maintaining epidermal homeostasis. PLoS One 2011, 6:e17867.
59. Lee D., Park S.J., Sung K.S., Park J., Lee S.B., Park S.Y., et al. Mdm2 associates with Ras effector NORE1 to induce the degradation of oncoprotein HIPK1. EMBO Rep 2012, 13:163-169.
60. Liu G., Yin B., Song Y.S. Methylation and protein expression of RASSF2 in prostate cancer. Zhonghua Nan Ke Xue 2013, 19:107-110.
61. Lock F.E., Underhill-Day N., Dunwell T., Matallanas D., Cooper W., Hesson L., et al. The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways. Oncogene 2010, 29:4307-4316.
62. Macheiner D., Heller G., Kappel S., Bichler C., Stattner S., Ziegler B., et al. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol 2006, 45:81-89.
63. Macheiner D., Gauglhofer C., Rodgarkia-Dara C., Grusch M., Brachner A., Bichler C., et al. NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Res 2009, 69:235-242.
64. Makbul C., Constantinescu Aruxandei D., Hofmann E., Schwarz D., Wolf E., Herrmann C. Structural and thermodynamic characterization of Nore1-SARAH: a small, helical module important in signal transduction networks. Biochemistry 2013, 52:1045-1054.
65. Malpeli G., Amato E., Dandrea M., Fumagalli C., Debattisti V., Boninsegna L., et al. Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. BMC Cancer 2011, 11:351.
66. Matallanas D., Romano D., Yee K., Meissl K., Kucerova L., Piazzolla D., et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 2007, 27:962-975.
67. Miertzschke M., Stanley P., Bunney T.D., Rodrigues-Lima F., Hogg N., Katan M. Characterization of interactions of adapter protein RAPL/Nore1B with RAP GTPases and their role in T cell migration. J Biol Chem 2007, 282:30629-30642.
68. Moshnikova A., Frye J., Shay J.W., Minna J.D., Khokhlatchev A.V. The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. J Biol Chem 2006, 281:8143-8152.
69. Moshnikova A., Kuznetsov S., Khokhlatchev A.V. Interaction of the growth and tumour suppressor NORE1A with microtubules is not required for its growth-suppressive function. BMC Res Notes 2008, 1:13.
70. Oceandy D., Pickard A., Prehar S., Zi M., Mohamed T.M., Stanley P.J., et al. Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation 2009, 120:607-616.
71. Oh H.J., Lee K.K., Song S.J., Jin M.S., Song M.S., Lee J.H., et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006, 66:2562-2569.
72. Ortiz-Vega S., Khokhlatchev A., Nedwidek M., Zhang X.F., Dammann R., Pfeifer G.P., et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002, 21:1381-1390.
73. Park J., Kang S.I., Lee S.Y., Zhang X.F., Kim M.S., Beers L.F., et al. Tumor suppressor Ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J Biol Chem 2010, 285:35029-35038.
74. Park S.J., Lee D., Choi C.Y., Ryu S.Y. Induction of apoptosis by NORE1A in a manner dependent on its nuclear export. Biochem Biophys Res Commun 2008, 368:56-61.
75. Peng H., Liu H., Zhao S., Wu J., Fan J., Liao J. Silencing of RASSF3 by DNA hypermethylation is associated with tumorigenesis in somatotroph adenomas. PLoS One 2013, 8:e59024.
76. Pfeifer G.P., Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry 2005, 70:576-583.
77. Praskova M., Khoklatchev A., Ortiz-Vega S., Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J 2004, 381:453-462.
78. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011, 11:761-774.
79. Raab M., Wang H., Lu Y., Smith X., Wu Z., Strebhardt K., et al. T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity 2010, 32:541-556.
80. Raab M., Smith X., Matthess Y., Strebhardt K., Rudd C.E. SKAP1 protein PH domain determines RapL membrane localization and Rap1 protein complex formation for T cell receptor (TCR) activation of LFA-1. J Biol Chem 2011, 286:29663-29670.
81. Recino A., Sherwood V., Flaxman A., Cooper W.N., Latif F., Ward A., et al. Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis. Biochem J 2010, 430:207-213.
82. Reeves M., Baldwin M., Aragon R., Baldwin S., Chen S., Li X., et al. RASSF1C modulates the expression of a stem cell renewal gene, PIWIL1. BMC Res Notes 2012, 16:239.
83. Reeves M.E., Baldwin S.W., Baldwin M.L., Chen S.T., Moretz J.M., Aragon R.J., et al. Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis. BMC Cancer 2010, 10:562.
84. Richter A.M., Pfeifer G.P., Dammann R.H. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009, 1796:114-128.
85. Richter A.M., Walesch S.K., Wurl P., Taubert H., Dammann R.H. The tumor suppressor RASSF10 is upregulated upon contact inhibition and frequently epigenetically silenced in cancer. Oncogenesis 2012, 1:e18.
86. Rodriguez-Viciana P., Sabatier C., McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004, 24:4943-4954.
87. Rong R., Jin W., Zhang J., Sheikh M.S., Huang Y. Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 2004, 23:8216-8230.
88. Rong R., Jiang L.Y., Sheikh M.S., Huang Y. Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene 2007, 26:7700-7708.
89. Sanada Y., Kumoto T., Suehiro H., Nishimura F., Kato N., Hata Y., et al. RASSF6 expression in adipocytes is down-regulated by interaction with macrophages. PLoS One 2013, 8:e61931.
90. Schagdarsurengin U., Seidel C., Ulbrich E.J., Kolbl H., Dittmer J., Dammann R. A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast. Int J Oncol 2005, 27:185-191.
91. Schagdarsurengin U., Richter A., Wöhler C., Dammann R. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 2009, 4:571-576.
92. Schagdarsurengin U., Richter A.M., Hornung J., Lange C., Steinmann K., Dammann R.H. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010, 9:264.
93. Scrace S.F., O'Neill E. RASSF signalling and DNA damage: monitoring the integrity of the genome?. Mol Biol Int 2012, 2012:141732.
94. Sherwood V., Manbodh R., Sheppard C., Chalmers A.D. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 2008, 19:1772-1782.
95. Sherwood V., Recino A., Jeffries A., Ward A., Chalmers A.D. The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 2010, 425:303-311.
96. Song H., Oh S., Oh H.J., Lim D.S. Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem Biophys Res Commun 2010, 391:969-973.
97. Song H., Kim H., Lee K., Lee D.H., Kim T.S., Song J.Y., et al. Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice. EMBO J 2012, 31:1147-1159.
98. Song M.S., Song S.J., Ayad N.G., Chang J.S., Lee J.H., Hong H.K., et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004, 6:129-137.
99. Song M.S., Song S.J., Kim S.J., Nakayama K., Nakayama K.I., Lim D.S. Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1-S transition. Oncogene 2008, 27:3176-3185.
100. Song S.J., Song M.S., Kim S.J., Kim S.Y., Kwon S.H., Kim J.G., et al. Aurora A regulates prometaphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity. Cancer Res 2009, 69:2314-2323.
101. Sorli S.C., Bunney T.D., Sugden P.H., Paterson H.F., Katan M. Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants. Oncogene 2005, 24:90-100.
102. Stieglitz B., Bee C., Schwarz D., Yildiz O., Moshnikova A., Khokhlatchev A., et al. Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J 2008, 27:1995-2005.
103. Suryaraja R., Anitha M., Anbarasu K., Kumari G., Mahalingam S. The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner. Cell Death Dis 2013, 4:e565.
104. Takahashi S., Ebihara A., Kajiho H., Kontani K., Nishina H., Katada T. RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting the activity of phosphorylated-MKK7. Cell Death Differ 2011, 18:645-655.
105. Thaler S., Hahnel P.S., Schad A., Dammann R., Schuler M. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res 2009, 69:1748-1757.
106. Tommasi S., Dammann R., Jin S.-g., Zhang X.-f., Avruch J. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 2002, 21:2713-2720.
107. Underhill-Day N., Hill V., Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011, 6:284-292.
108. van der Weyden L., Adams D.J. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007, 1776:58-85.
109. Vavvas D. Identification of Nore1 as a potential Ras effector. J Biol Chem 1998, 273:5439-5442.
110. Verma S.K., Ganesan T.S., Kishore U., Parker P.J. The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A. Protein Cell 2011, 2:237-249.
111. Vos M.D., Ellis C.A., Bell A., Birrer M.J., Clark G.J. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000, 275:35669-35672.
112. Vos M.D., Ellis C.A., Elam C., Ulku A.S., Taylor B.J., Clark G.J. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003, 278:28045-28051.
113. Vos M.D., Martinez A., Ellis C.A., Vallecorsa T., Clark G.J. The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 2003, 278:21938-21943.
114. Vos M.D., Dallol A., Eckfeld K., Allen N.P., Donninger H., Hesson L.B., et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem 2006, 281:4557-4563.
115. Wang X., Zhou C., Qiu G., Fan J., Tang H., Peng Z. Screening of new tumor suppressor genes in sporadic colorectal cancer patients. Hepatogastroenterology 2008, 55:2039-2044.
116. Wang X., Zhou C., Qiu G., Yang Y., Yan D., Xing T., et al. Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer. Med Oncol 2012, 29:1051-1058.
117. Wei Z., Chen X., Chen J., Wang W., Xu X., Cai Q. RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer. Biochem Biophys Res Commun 2013, 432:632-637.
118. Weitzel J.N., Kasperczyk A., Mohan C., Krontiris T.G. The HRAS1 gene cluster: two upstream regions recognizing transcripts and a third encoding a gene with a leucine zipper domain. Genomics 1992, 14:309-319.
119. Welcsh P.L., Lee M.K., Gonzalez-Hernandez R.M., Black D.J., Mahadevappa M., Swisher E.M., et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A 2002, 99:7560-7565.
120. Wen Y., Wang Q., Zhou C., Yan D., Qiu G., Yang C., et al. Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery. Ann Surg Oncol 2011, 18:3858-3867.
121. Zhou X., Li T.T., Feng X., Hsiang E., Xiong Y., Guan K.L., et al. Targeted polyubiquitylation of RASSF1C by the Mule and SCFbeta-TrCP ligases in response to DNA damage. Biochem J 2012, 441:227-236.